Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 28, 2009

View Archived Issues

Computational biology approach indicates potential for entacapone in tuberculosis

Locus Pharmaceuticals selects novel allosteric p38 inhibitor for development

Program at TetraLogic yields Smac mimetics with antitumor activity

Nociceptin receptor agonist from Schering-Plough displays antitussive activity in vivo

Dyax presents update on licensing and funded research program

Resverlogix reports results from phase Ib/IIa RVX-208 study for atherosclerosis

EMEA approves Huntexil as trade name for NeuroSearch's pridopidine for HD

Astellas and Pfizer sign copromotion agreement for Caduet

Chugai reports results from second quarter 2009

Diamyd to include children and accelerate recruitment in phase III diabetes trial

Endo to partner with ProStrakan to commercialize Fortesta in the U.S.

Wyeth tests novel 5-HT1A antagonists for cognitive enhancement

Amgen reports on oncolytic small-molecule Smoothened antagonists

Genmab reports topline results for Arzerra in non-Hodgkin's lymphoma

NIAID awards grant to expand studies of anti-PS antibodies for hemorrhagic fevers

EMEA accepts for review Schering-Plough's MAAs for asthma drug and contraceptive

Silence Therapeutics enters siRNA delivery collaboration with Dainippon Sumitomo

UCB and Immunomedics report topline results from phase IIb epratuzumab study in SLE

Gruenenthal discloses novel bradykinin B1 receptor antagonists for pain treatment

RNA-directed RNA polymerase (NS5B) inhibitors patented by Tibotec

Merck Serono claims protein kinase inhibitors for cancer, inflammatory disorders

Novel beta-lactams in early development at Allergan

Lactam inhibitors of 11-beta-HSD1 presented by Vitae Pharmaceuticals

Novel orexin receptor antagonists identified at Roche

Oxagen develops CRTH2 receptor antagonists for treating allergic diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...